{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:27:43Z","timestamp":1793485663849,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-hoi250034-4\"><jats:title>Importance<\/jats:title><jats:p>Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy reduces risk of heart failure (HF) events and cardiovascular death among individuals with HF. Trends of SGLT2i use in cardiovascular ambulatory care in the US remain unknown.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi250034-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the rate of SGLT2i use among patients with HF in the cardiovascular ambulatory care setting.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi250034-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a retrospective cohort study conducted from July 1, 2019, through June 30, 2023. Included for analysis were patients with HF enrolled in the National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence (PINNACLE) registry, a national ambulatory cardiovascular care quality improvement registry. Study data were analyzed from February 15, 2024, through January 15, 2025.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi250034-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Patient-level and practice-level prescription of SGLT2i therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi250034-8\"><jats:title>Results<\/jats:title><jats:p>Of 759\u202f915 patients (mean [SD] age, 70 [14] years; 359\u202f270 women [47.3%]; 49\u202f252 Black individuals [14.6%]; 278\u202f303 White individuals [82.7%]) with HF at 191 US sites, 76\u202f927 (10.1%) were prescribed SGLT2i. Among patients with available ejection fraction (EF) data, 20\u202f544 (17.9%) with HF with reduced EF (HFrEF) and 36\u202f615 (8.9%) with HF with mildly reduced EF (HFmrEF) or HF with preserved EF (HFpEF) were prescribed SGLT2i. Rates of SGLT2i use for all patients with HF increased from 4.6% in the third quarter of 2019 to 16.2% in the second quarter of 2023, from 5.1% to 28.5% for those with HFrEF, and from 4.5% to 12.8% for those with HFmrEF or HFpEF (<jats:italic>P<\/jats:italic> for trend &amp;amp;lt;.001). SGLT2i was less commonly used for older persons (IQR age, 80 years vs 63 years; OR, 0.76; 95% CI, 0.75-0.77), female sex (OR, 0.79; 95% CI, 0.77-0.81), and higher systolic blood pressure (OR, 0.78; 95% CI, 0.77-0.79), whereas history of type 2 diabetes was associated with markedly higher use (OR, 3.21; 95% CI, 3.15-3.28). After adjustment for patient- and practice-level characteristics, significant variation in SGLT2i use across sites was present (90th vs 10th percentile risk practice, adjusted OR, 4.40; 95% CI, 3.76-5.52).<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi250034-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Although this study found that SGLT2i use had increased among ambulatory patients with HF during the study period, the majority of eligible patients did not receive this therapy. Older age, female sex, and higher blood pressures were associated with lower SGLT2i use with significant unexplained variation in use across practices. Systematic efforts to improve SGLT2i therapy use are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.2145","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:00:36Z","timestamp":1752073236000},"page":"904","source":"Crossref","is-referenced-by-count":13,"title":["Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care"],"prefix":"10.1001","volume":"10","author":[{"given":"Abdelghani","family":"El Rafei","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensey","family":"Gosch","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, St Luke\u2019s Mid America, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Manning","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ghajar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Academic Primary Care Division, Rocky Mountain Regional VA Medical Center, Aurora, Colorado"},{"name":"Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Maddox","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora"},{"name":"Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Fleming","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne V.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, St Luke\u2019s Mid America, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, St Luke\u2019s Mid America, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of California, Los Angeles"},{"name":"Associate Section Editor, JAMA Cardiology\ufeff"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, St Luke\u2019s Mid America, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Hess","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"hoi250034r1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi250034r2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi250034r3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi250034r4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"hoi250034r5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"37","key":"hoi250034r6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi250034r7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamacardio.2022.4348","article-title":"Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US.","volume":"8","author":"Talha","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"7","key":"hoi250034r8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get With the Guidelines-Heart Failure Registry.","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hoi250034r9","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.cardfail.2023.12.018","article-title":"Uptake of sodium-glucose cotransporter-2 inhibitors in hospitalized patients with heart failure: insights from the Veterans Affairs healthcare system.","volume":"30","author":"Varshney","year":"2024","journal-title":"J Card Fail"},{"issue":"1","key":"hoi250034r10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2024.4489","article-title":"Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction.","volume":"10","author":"Abdel Jawad","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi250034r11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.amjcard.2011.06.017","article-title":"Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program).","volume":"108","author":"Chan","year":"2011","journal-title":"Am J Cardiol"},{"issue":"1","key":"hoi250034r12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacc.2019.11.011","article-title":"Trends in U.S. ambulatory cardiovascular care 2013 to 2017: JACC review topic of the week.","volume":"75","author":"Maddox","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hoi250034r13","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2013.05.099","article-title":"Cardiovascular care facts: a report from the national cardiovascular data registry: 2011.","volume":"62","author":"Masoudi","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi250034r14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jchf.2024.02.014","article-title":"National trends in hospital performance in guideline-recommended pharmacologic treatment for heart failure at discharge.","volume":"12","author":"Hess","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"3","key":"hoi250034r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Software"},{"issue":"1","key":"hoi250034r16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12874-018-0517-7","article-title":"Reference effect measures for quantifying, comparing and visualizing variation from random and fixed effects in non-normal multilevel models, with applications to site variation in medical procedure use and outcomes.","volume":"18","author":"Glorioso","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"hoi250034r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types.","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"4","key":"hoi250034r18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"hoi250034r19","first-page":"1219","article-title":"FDA expands empagliflozin heart failure indication.","volume":"327","author":"Larkin","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"hoi250034r20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","article-title":"Applicability of US Food and Drug Administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in us clinical practice: the Get With the Guidelines-Heart Failure (GWTG-HF) registry.","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"key":"hoi250034r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100814","article-title":"Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.","volume":"36","author":"Narasaki","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"hoi250034r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age.","volume":"80","author":"B\u00f6hm","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi250034r23","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi250034r24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF.","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"hoi250034r25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial.","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"14","key":"hoi250034r26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.122.059755","article-title":"Effects of empagliflozin in women and men with heart failure and preserved ejection fraction.","volume":"146","author":"Butler","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"hoi250034r27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamacardio.2021.0379","article-title":"Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.","volume":"6","author":"Butt","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi250034r28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER.","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"hoi250034r29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.","volume":"44","author":"B\u00f6hm","year":"2023","journal-title":"Eur Heart J"},{"issue":"13","key":"hoi250034r30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure.","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250034r31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER.","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"36","key":"hoi250034r32","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"hoi250034r33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial.","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"hoi250034r34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"14","key":"hoi250034r35","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of Dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"hoi250034r36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2018.09.081","article-title":"Differential impact of heart failure with reduced ejection fraction on men and women.","volume":"73","author":"Dewan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi250034r37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jchf.2019.03.011","article-title":"Sex-Based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications.","volume":"7","author":"Stolfo","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"8 Pt 1","key":"hoi250034r38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jchf.2023.04.015","article-title":"Opportunities and achievement of medication initiation among inpatients with heart failure with reduced ejection fraction.","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"2","key":"hoi250034r39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/dom.13510","article-title":"Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: a national cardiovascular data registry \u201cresearch-to-practice\u201d project from the diabetes collaborative registry.","volume":"21","author":"Arnold","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"hoi250034r40","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi250034r41","doi-asserted-by":"publisher","first-page":"e245135","DOI":"10.1001\/jamanetworkopen.2024.5135","article-title":"SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis.","volume":"7","author":"Gao","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"hoi250034r42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000409.pub2","article-title":"Educational outreach visits: effects on professional practice and health care outcomes.","volume":"2007","author":"O\u2019Brien","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"hoi250034r43","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jchf.2023.06.022","article-title":"Clinical inertia among outpatients with heart failure: application of treatment nonintensification taxonomy to EPIC-HF trial.","volume":"11","author":"Swat","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"7","key":"hoi250034r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101014","article-title":"County-level variation in triple guideline-directed medical therapy in heart failure with reduced ejection fraction.","volume":"3","author":"Desai","year":"2024","journal-title":"JACC Adv"},{"issue":"22","key":"hoi250034r45","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial.","volume":"79","author":"Ghazi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi250034r46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","article-title":"An Electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial.","volume":"143","author":"Allen","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"hoi250034r47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/archinte.168.7.687","article-title":"Pharmacist care of patients with heart failure: a systematic review of randomized trials.","volume":"168","author":"Koshman","year":"2008","journal-title":"Arch Intern Med"},{"issue":"11","key":"hoi250034r48","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.120.053291","article-title":"The affordability of guideline-directed medical therapy: cost sharing is a critical barrier to therapy adoption.","volume":"143","author":"Sandhu","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"hoi250034r49","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2835677\/jamacardiology_el_rafei_2025_oi_250034_1757354393.4833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:01:04Z","timestamp":1757516464000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2835677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.2145","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}